Jianpi Qinghua Formula improves metabolic-associated fatty liver disease by modulating PGC1α/PPARα/CPT1A pathway.
10.19540/j.cnki.cjcmm.20250212.501
- Author:
Yan-Yan XIAO
1
;
Xu HAN
1
;
Qing-Guang CHEN
1
;
Jun-Fei XU
1
;
Chi CHEN
1
;
Fan GONG
1
;
Hao LU
1
Author Information
1. Shuguang Hospital, Shanghai University of Traditional Chinese Medicine Shanghai 200021, China.
- Publication Type:Journal Article
- Keywords:
PGC1α/PPARα/CPT1A pathway;
fatty acid β-oxidation;
metabolic-associated fatty liver disease
- MeSH:
Animals;
PPAR alpha/genetics*;
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/genetics*;
Drugs, Chinese Herbal/administration & dosage*;
Mice;
Carnitine O-Palmitoyltransferase/genetics*;
Male;
Liver/metabolism*;
Fatty Liver/genetics*;
Humans;
Mice, Inbred C57BL;
Diet, High-Fat/adverse effects*
- From:
China Journal of Chinese Materia Medica
2025;50(9):2505-2514
- CountryChina
- Language:Chinese
-
Abstract:
Based on the regulation of mitochondrial fatty acid β-oxidation through the PGC1α/PPARα/CPT1A pathway, this study investigated the effect of Jianpi Qinghua Formula on the mitochondrial fatty acid β-oxidation pathway in the livers of mice with metabolic-associated fatty liver disease(MAFLD) induced by a high-fat diet. MAFLD mice were fed a high-fat diet to establish the model, and after successful modeling, the mice were divided into the model group, the Jianpi Qinghua Formula group, and the metformin group, with an additional control group. Each group was treated with the corresponding drug or an equivalent volume of saline via gavage. Body mass and food intake were measured regularly during the experiment. At the end of the experiment, blood lipid levels and liver function-related indices were measured, liver pathological changes were observed, and protein expression levels of PGC1α, PPARα, PPARγ, and CPT1A were detected by Western blot. The results showed that, with no difference in food intake, compared to the model group, the body mass of the Jianpi Qinghua Formula group and the metformin group was reduced, liver weight and liver index decreased, and levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol(LDL-C) were lowered. Additionally, a decrease in alanine aminotransferase(ALT) and aspartate aminotransferase(AST) was observed. Hematoxylin and eosin(HE) staining revealed reduced pathological damage to hepatocytes, while oil red O staining showed improvement in fatty infiltration. The liver disease activity score decreased, and transmission electron microscopy revealed improvement in mitochondrial swelling and restoration of internal cristae. Western blot analysis indicated that Jianpi Qinghua Formula significantly increased the expression of PGC1α, PPARα, and CPT1A proteins in the liver and reduced the expression of PPARγ. These results suggest that the Jianpi Qinghua Formula improves mitochondrial function, promotes fatty acid oxidation, and alleviates the pathological changes of MAFLD. In conclusion, Jianpi Qinghua Formula can improve MAFLD by mediating mitochondrial fatty acid β-oxidation through the PGC1α/PPARα/CPT1A pathway.
